Woodcock, J. (2021). FDA Issues First Notice of Noncompliance for Failure to Submit Clinical Trial Results: FDA Statement of Enforcement of clinicalTrials.gov Reporting Requirements. JAMA Health Forum, Vol. 2.

has been cited by the following article:

• TITLE: Beyond the Magic Pill: Reassessing the Role of Pharmacology in Autism Care through Restorative Perspectives

  AUTHORS: Geoffrey A. Johnson

  KEYWORDS: Autism, Clinical Trials, Ethics, Inclusion, Medications, Neurodiversity, Pharmacology

  JOURNAL NAME: Open Journal of Social Sciences, Vol.13 No.9, September 22, 2025

  ABSTRACT: This article examines dominant pharmacological treatment approaches in autism care. By analyzing existing clinical practices, it critiques medicalized frameworks for autism intervention and introduces restorative justice principles as a neurodiversity-affirming model to reimagine relational, community-centered care. These frameworks emphasize the inclusion of the autism community, parents, and primary caregivers in treatment decision-making, particularly regarding the selection and testing of medications. Such care must be balanced with individualized supports and evidence-based behavioral frameworks. Through narrative analysis and targeted pharmacological comparisons, the article highlights systemic barriers, ethical tensions, and the underrepresented voices of autistic individuals and caregivers in clinical settings. The findings advocate for transparent and inclusive models of care that position autistic individuals as co-creators of their health and well-being.